Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Department of Pediatrics Harvard Medical School, Boston, Massachusetts.
JAMA Pediatr. 2018 Dec 1;172(12):e183310. doi: 10.1001/jamapediatrics.2018.3310. Epub 2018 Dec 3.
American Heart Association guidelines recommend echocardiography in Kawasaki disease at baseline, 1 to 2 weeks, and 4 to 6 weeks after treatment to detect coronary artery abnormalities. However, these examinations are expensive and may require sedation in young children, which is burdensome and carries some risk.
To assess the benefit of additional echocardiographic imaging at 6 weeks in patients with uncomplicated Kawasaki disease who had previously normal coronary arteries.
DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective review of patients with Kawasaki disease who were cared for between 1995 and 2014 in 2 academic pediatric referral practices Eligibility criteria included receiving intravenous immunoglobulin treatment for acute Kawasaki disease at a center; the absence of significant congenital heart disease; available echocardiographic measurements of both the right and left anterior descending coronary arteries at 10 days or less after diagnosis (baseline), 2 (±1) weeks, and 6 (±3) weeks of illness; and normal coronary arteries at baseline and 2 weeks, defined as maximum coronary artery z scores less than 2.0 and no distal aneurysms. Data analysis was completed from March 2015 to November 2015.
The number of patients with right coronary artery or left anterior descending coronary artery z scores of 2.0 or more at 6 weeks.
The median age of the 464 included patients was 3.3 years (interquartile range, 1.8-5.4 years); 264 (56.9%) were male, 351 of 414 for whom data were available (84.8%) had complete Kawasaki disease, and 66 (14.2%) received additional intravenous immunoglobulin treatment. At 6 weeks of illness, 456 patients (98.3%) who had had normal coronary artery z scores at baseline and 2 weeks continued to have normal z scores. Of the remaining 8 patients (1.7%), the maximum z score within 6 weeks was 2.0 to 2.4 in 5 patients (1.2%), 2.5 to 2.9 in 1 patient (0.2%), and 3.0 or more in 2 patients (0.4% [95% CI, 0.1%-1.5%]). Coronary artery dimensions ultimately normalized in all but 1 patient, who had minimal dilation at 6 weeks (right coronary artery z score, 2.1). Sensitivity analyses using less restrictive cut points (eg, a maximum z score <2.5) or less restrictive timing windows (eg, considering patients with incomplete echocardiographic data within 21 days) gave similar results; in these analyses, 454 to 463 of 464 patients (98% to 99.7%) had coronary artery z scores of less than 2.5 at 6 weeks.
New abnormalities in coronary arteries are rarely detected at 6 weeks in patients with Kawasaki disease who have normal measurements at baseline and 2 weeks of illness, suggesting that the 6-week echocardiographic imaging may be unnecessary in patients with uncomplicated Kawasaki disease and z scores less than 2.0 in the first 2 weeks of illness.
美国心脏协会指南建议在川崎病治疗后基线、1-2 周和 4-6 周进行超声心动图检查,以检测冠状动脉异常。然而,这些检查费用昂贵,可能需要在年幼的孩子中进行镇静,这是繁琐的,并存在一定的风险。
评估在先前冠状动脉正常的无并发症川崎病患者中,在 6 周时进行额外超声心动图检查的益处。
设计、地点和参与者:这是一项对 1995 年至 2014 年期间在 2 个学术儿科转诊中心接受治疗的川崎病患者进行的回顾性研究。入选标准包括在中心接受静脉注射免疫球蛋白治疗急性川崎病;无明显先天性心脏病;在诊断后 10 天或更短时间内(基线)、2(±1)周和 6(±3)周时均有右前降支冠状动脉和左前降支冠状动脉的超声心动图测量值;基线和 2 周时冠状动脉正常,定义为最大冠状动脉 z 评分小于 2.0,无远端动脉瘤。数据分析于 2015 年 3 月至 2015 年 11 月完成。
6 周时右冠状动脉或左前降支冠状动脉 z 评分大于等于 2.0 的患者人数。
464 例纳入患者的中位年龄为 3.3 岁(四分位距,1.8-5.4 岁);264 例(56.9%)为男性,414 例(84.8%)有完整的川崎病数据,66 例(14.2%)接受了额外的静脉注射免疫球蛋白治疗。在疾病的第 6 周,456 例(98.3%)基线和 2 周时冠状动脉 z 评分正常的患者继续保持正常 z 评分。其余 8 例(1.7%)患者中,5 例(1.2%)的最大 z 评分在 6 周内为 2.0 至 2.4,1 例(0.2%)为 2.5 至 2.9,2 例(0.4%[95%CI,0.1%-1.5%])为 3.0 或更高。除 1 例患者外,所有患者的冠状动脉直径最终均恢复正常,该患者在 6 周时仅有轻微扩张(右冠状动脉 z 评分 2.1)。使用更严格的截止值(例如,最大 z 评分<2.5)或更严格的时间窗(例如,考虑在 21 天内进行不完全超声心动图检查的患者)进行的敏感性分析得出了类似的结果;在这些分析中,454 例至 464 例患者(98%至 99.7%)在 6 周时的冠状动脉 z 评分小于 2.5。
在基线和疾病第 2 周时冠状动脉测量值正常的川崎病患者中,很少在第 6 周时发现新的冠状动脉异常,这表明在无并发症川崎病患者和第 2 周内 z 评分小于 2.0 的患者中,第 6 周的超声心动图检查可能不必要。